Antibacterial Drugs Market To Witness Stellar Revenue Growth Across Top Regional Pockets : Fact.MR

A recently published report by Fact.MR reveals that the global antibacterial drugs market is projected to grow at a modest CAGR of 2.6% during the forecast period (2021-2031), expected to reach a value of US$ 62 Bn. In the short run, the market is poised to expand at a CAGR of 1.5% from 2020-2025 to reach US$ 50 Bn.

Historically, the market experienced sluggish growth, registering a 1% value CAGR from 2016 to 2020. At the end of the said historical period, the market was valued at around US$ 46 Bn. By 2021, it is likely to be valued at US$ 48 Bn. Prospects have dimmed majorly amidst the COVID-19 pandemic, with pharmaceutical companies shifting focus towards developing effective anti-viral vaccinations and drugs. This exercise is bound to consume a major part of their finances, relegating prospects for antibacterial drugs.

At the same time, factors such as an increase in the ageing population, growing demand for efficient and affordable antibacterial drugs, and an increasing number of multi-drug resistant bacterial strains are driving the global antibacterial drugs market.

For critical insights on this market, request for More Info - https://www.factmr.com/connectus/sample?flag=S&rep_id=4340

Key Segments Covered

Drug Class
β-lactam Antibacterial Drugs
Quinolone Antibacterial Drugs
Macrolide Antibacterial Drugs
Tetracycline Antibacterial Drugs
Aminoglycoside Antibacterial Drugs
Sulfonamide Antibacterial Drugs
Phenicols Antibacterial Drugs
Other Antibacterial Drugs

Route of Administration
Enteral Antibacterial Drug Administration
Parenteral Antibacterial Drug Administration
Other Antibacterial Drug Administration Routes (Inhalation, Topical, etc.)

Distribution Channel
Antibacterial Drug Sales via Hospital Pharmacies
Antibacterial Drug Sales via Drug Stores and Retail Pharmacies
Online Antibacterial Drug Sales

Request more information about Report Methodology - https://www.factmr.com/connectus/sample?flag=RM&rep_id=4340

Key Takeaways from the Market Study

Demand for β-lactams to expand fastest, registering a 2% value CAGR
Drug stores and retail pharmacies to account for 2/5th of global sales until 2031
Patients' proclivity for enteral drugs is projected to increase, on account of oral therapy and relatively safe use than the parenteral route of administration.
North America is projected to hold 33% of global antibacterial drugs demand
Asia to emerge the dominant market, capturing 50% of overall demand for antibacterial drugs
Europe to capture 35% market share for antibacterial drugs across the forecast period

Competitive Landscape

Competition in the global market for antibacterial drugs is expected to rise, with players focusing on gaining competitive advantage and increasing their market foothold. Manufacturers can seek partnerships with government organizations to gain financial support for the development of drugs, and, in turn, position themselves as distinguished players in the global market.

In September 2021, Myovant Sciences and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) accepted for review a supplemental New Drug Application (sNDA) for MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) for the management of moderate to severe pain associated with endometriosis.

In July 2021, AstraZeneca announced that it has entered into a collaboration with Regeneron to research, develop and commercialize small molecule compounds directed against the GPR75 target with the potential to treat obesity and related co-morbidities.

For in-depth competitive analysis, Now - https://www.factmr.com/checkout/4340

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Email : sales@factmr.com
Website : https://www.factmr.com

Market research and consulting agency with a difference! That's why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range - from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analysed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we'll be an able research partner.

This release was published on openPR.